What question did this study set out to answer?

Assess the efficacy of asciminib in treating relapsed or refractory Ph+ ALL and LBC-CML in Italy.

December 8, 2025Blood

Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study

View Full Paper

Ask AI

Bookmark

Assess the efficacy of asciminib in treating relapsed or refractory Ph+ ALL and LBC-CML in Italy.
Retrospective evaluation of patients treated with asciminib
Data collected from a compassionate use program
Analysis of mutations in ABL1 TK domain
Thirteen patients achieved complete hematologic remission
Median overall survival not reached; 1-year OS estimated at 62.9%
Significant survival benefit observed with combination therapy (p = 0.02)

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows asciminib improves overall survival in relapsed Ph+ ALL and LBC-CML, highlighting its role as a TKI.

Rivoli et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark